BRET publication compilation
A compilation of scientific articles using Mithras or Tristar microplate readers for BRET.
EN | PDF | 511.6 KB
Download nowBRET (Bioluminescence Resonance Energy Transfer) is one of the key methods in studying PPI. While FRET is also quite popular, BRET is in many cases a better alternative, as it has a much lower background. BRET is very popular in the field of G-protein coupled receptor research, which is very important in drug discovery: currently ~30 % of drugs are targeted against GPCRs, but only 5 % of the known receptors are targeted with drugs.
Other methods covered in our selection of articles are HTRF® and Nano-BiT®, a commercial protein complementation assay.
Methods used to study protein-protein interactions are also useful to study protein trafficking: if a protein of interest interacts with a protein located, for example, in the plasmatic membrane, this indicates that it has been translocated to the plasmatic membrane. You can see examples of this approach in some of the publications below.
Microplate readers for BRET and more
We have been working closely with the BRET community since the introduction of our first multimode reader, the Mithras LB 940. Nowadays, the Tristar 3 continues this tradition, but at a fraction of the cost. This filter-based multimode reader measures absorbance, fluorescence and luminescence with great performance without breaking the bank. And, of course, filter sets are available for the most popular BRET assays!
If you need to measure TRF, TR-FRET, HTRF® or AlphaScreen®, or want the convenience of a monochromator, then the Tristar 5 is the best option for you.
Selected publications
| Year | Authors | Journal | Title | Relevant methods |
|---|---|---|---|---|
| 2021 | Bas Brouwers, Edson Mendes de Oliveira, Maria Marti-Solano, et al. | Cell Reports | BRET (protein trafficking) | |
| 2021 | Shane C. Wright, Viktoriya Lukasheva, Christian Le Gouill, et al. | PNAS | BRET (protein trafficking) | |
| 2020 | Jérôme Granel, Roxane Lemoine, Eric Morello, et al. | Frontiers in Immunology | HTRF® | |
| 2020 | Eline Pottiea, Peter Dedeckerb, Christophe P. Stove | Biochemical Pharmacology | NanoBiT® | |
| 2020 | Isra Al Zamel, Abdulrasheed Palakkott, Arshida Ashraf, et al. | Frontiers in Pharmacology | BRET | |
| 2019 | Soon Gang Choi, Julien Olivet, Patricia Cassonnet, et al. | Nature Communications | Maximizing binary interactome mapping with a minimal number of assays | NanoLuc two-hybrid (N2H) |
| 2019 | Alexandre Connolly, Brian J. Holleran, Élie Simard, et al. | Biochemical Pharmacology | BRET | |
| 2019 | Maja Susec, Milan Sencanski, Sanja Glisic, et al. | Neuropharmacology | Functional characterization of β2-adrenergic and insulin receptor heteromers | BRET |
| 2019 | Elise Wouters, Adrián R. Marín, James A.R. Dalton, et al. | International Journal of Molecular Sciences | Distinct Dopamine D2 Receptor Antagonists Differentially Impact D2 Receptor Oligomerization | NanoBiT® |
| 2018 | Matthieu Masureel, Yaozhong Zou, Louis-Philippe Picard, et al. | Nature Chemical Biology | Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist | BRET |
BRET publications
HTRF® is a registered trademark of Cisbio Bioassays.
NanoBiT® is a registered trademark of Promega Corporation.